The FDA approved donanemab, which will be sold under the brand name Kisunla. The new drug helps slow decline in Alzheimer's patients with mild cognitive impairment.

Called Donanemab, this treatment from Eli Lilly will be sold under its brand name, Kisunla, and works as an intravenous ...

The Food and Drug Administration last week approved donanemab, or Kisunla, an intravenous treatment for early stage Alzheimer ...

The FDA has recently approved Donanemab, a monoclonal antibody designed to slow the progression of early symptomatic ...

Learn about the benefits of Kisunla, the newly approved Alzheimer's drug that can modestly slow disease progression in the ...

It’s only the second drug that’s been convincingly shown to delay cognitive decline in patients, following last year’s approval of a similar drug from Japanese drugmaker Eisai.

Join Fox News for access to this content Plus special access to select articles and other premium content with your account - free of charge. By entering your email and pushing continue, you are ...

The Food and Drug Administration recently approved a new drug called 'Donanemab' to treat the debilitating Alzheimer's ...

The FDA-approved drug, Kisunla, produced by Eli Lilly, can slow the brain's decline in the early stages of the disease.

setting the stage for the FDA’s signoff. Eli Lilly’s drug — Kisunla, the brand name for donanemab — is one of the few treatments developed for Alzheimer’s that modifies the underlying disease and will ...

SARASOTA, Fla. (SNN) — The Food and Drug Administration has approved a new Alzheimer’s drug from Eli Lilly. According to Eli ...

(Scripps News) WASHINGTON — U.S. officials have approved another Alzheimer’s drug that can ... get a prescription. The FDA approved Kisunla, known chemically as donanemab, based on results ...